306 related articles for article (PubMed ID: 18560366)
1. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas.
Joo KM; Kim SY; Jin X; Song SY; Kong DS; Lee JI; Jeon JW; Kim MH; Kang BG; Jung Y; Jin J; Hong SC; Park WY; Lee DS; Kim H; Nam DH
Lab Invest; 2008 Aug; 88(8):808-15. PubMed ID: 18560366
[TBL] [Abstract][Full Text] [Related]
2. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
4. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
5. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous phenotype of human glioblastoma: in vitro study.
Denysenko T; Gennero L; Juenemann C; Morra I; Masperi P; Ceroni V; Pragliola A; Ponzetto A; Melcarne A
Cell Biochem Funct; 2014 Mar; 32(2):164-76. PubMed ID: 23836332
[TBL] [Abstract][Full Text] [Related]
7. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
[TBL] [Abstract][Full Text] [Related]
8. A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.
Liu XJ; Wu WT; Wu WH; Yin F; Ma SH; Qin JZ; Liu XX; Liu YN; Zhang XY; Li P; Han S; Liu KY; Zhang JM; He QH; Shen L
CNS Neurosci Ther; 2013 Jul; 19(7):494-502. PubMed ID: 23575351
[TBL] [Abstract][Full Text] [Related]
9. Selective lentiviral gene delivery to CD133-expressing human glioblastoma stem cells.
Bayin NS; Modrek AS; Dietrich A; Lebowitz J; Abel T; Song HR; Schober M; Zagzag D; Buchholz CJ; Chao MV; Placantonakis DG
PLoS One; 2014; 9(12):e116114. PubMed ID: 25541984
[TBL] [Abstract][Full Text] [Related]
10. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
Jamal M; Rath BH; Tsang PS; Camphausen K; Tofilon PJ
Neoplasia; 2012 Feb; 14(2):150-8. PubMed ID: 22431923
[TBL] [Abstract][Full Text] [Related]
11. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
12. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
[TBL] [Abstract][Full Text] [Related]
13. Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.
Wu A; Wiesner S; Xiao J; Ericson K; Chen W; Hall WA; Low WC; Ohlfest JR
J Neurooncol; 2007 Jun; 83(2):121-31. PubMed ID: 17077937
[TBL] [Abstract][Full Text] [Related]
14. A distinct subpopulation within CD133 positive brain tumor cells shares characteristics with endothelial progenitor cells.
Choi SA; Wang KC; Phi JH; Lee JY; Park CK; Park SH; Kim SK
Cancer Lett; 2012 Nov; 324(2):221-30. PubMed ID: 22652175
[TBL] [Abstract][Full Text] [Related]
15. Brain tumor stem cells from an adenoid glioblastoma multiforme.
Oka N; Soeda A; Noda S; Iwama T
Neurol Med Chir (Tokyo); 2009 Apr; 49(4):146-50; discussion 150-1. PubMed ID: 19398857
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
17. Rac1+ cells distributed in accordance with CD 133+ cells in glioblastomas and the elevated invasiveness of CD 133+ glioma cells with higher Rac1 activity.
Zhang B; Sun J; Yu SP; Chen C; Liu B; Liu ZF; Ren BC; Ming HL; Yang XJ
Chin Med J (Engl); 2012 Dec; 125(24):4344-8. PubMed ID: 23253699
[TBL] [Abstract][Full Text] [Related]
18. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
19. BMI1 sustains human glioblastoma multiforme stem cell renewal.
Abdouh M; Facchino S; Chatoo W; Balasingam V; Ferreira J; Bernier G
J Neurosci; 2009 Jul; 29(28):8884-96. PubMed ID: 19605626
[TBL] [Abstract][Full Text] [Related]
20. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
